ZA201002466B - Pyridazinone derivatives as parp inhibitors - Google Patents
Pyridazinone derivatives as parp inhibitorsInfo
- Publication number
- ZA201002466B ZA201002466B ZA2010/02466A ZA201002466A ZA201002466B ZA 201002466 B ZA201002466 B ZA 201002466B ZA 2010/02466 A ZA2010/02466 A ZA 2010/02466A ZA 201002466 A ZA201002466 A ZA 201002466A ZA 201002466 B ZA201002466 B ZA 201002466B
- Authority
- ZA
- South Africa
- Prior art keywords
- parp inhibitors
- pyridazinone derivatives
- pyridazinone
- derivatives
- parp
- Prior art date
Links
- AAILEWXSEQLMNI-UHFFFAOYSA-N 1h-pyridazin-6-one Chemical class OC1=CC=CN=N1 AAILEWXSEQLMNI-UHFFFAOYSA-N 0.000 title 1
- 239000012661 PARP inhibitor Substances 0.000 title 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0722401A GB0722401D0 (en) | 2007-11-15 | 2007-11-15 | Therapeutic compounds |
| GB0816707A GB0816707D0 (en) | 2008-09-12 | 2008-09-12 | Therapeutic compounds |
| PCT/GB2008/051063 WO2009063244A1 (en) | 2007-11-15 | 2008-11-14 | Pyridazinone derivatives as parp inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201002466B true ZA201002466B (en) | 2010-12-29 |
Family
ID=40427149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2010/02466A ZA201002466B (en) | 2007-11-15 | 2010-04-08 | Pyridazinone derivatives as parp inhibitors |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8268827B2 (https=) |
| EP (1) | EP2220073B1 (https=) |
| JP (1) | JP5758630B2 (https=) |
| KR (1) | KR101641596B1 (https=) |
| CN (1) | CN101855221B (https=) |
| AU (1) | AU2008322676B9 (https=) |
| CA (1) | CA2704714C (https=) |
| ES (1) | ES2524787T3 (https=) |
| IL (1) | IL205142A (https=) |
| MX (1) | MX2010005070A (https=) |
| NZ (1) | NZ585395A (https=) |
| RU (1) | RU2490265C2 (https=) |
| WO (1) | WO2009063244A1 (https=) |
| ZA (1) | ZA201002466B (https=) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120027177A (ko) * | 2009-04-02 | 2012-03-21 | 메르크 파텐트 게엠베하 | 오토탁신 저해제로서의 피페리딘 및 피라진 유도체 |
| US8609672B2 (en) | 2010-08-27 | 2013-12-17 | University Of The Pacific | Piperazinylpyrimidine analogues as protein kinase inhibitors |
| EP2686305B1 (en) * | 2011-03-14 | 2020-09-16 | Impact Therapeutics, Inc. | Quinazolinediones and their use |
| EP2714703B1 (en) | 2011-05-31 | 2021-03-10 | Newgen Therapeutics, Inc. | Tricyclic inhibitors of poly(adp-ribose)polymerase |
| IN2014DN06169A (https=) | 2011-12-31 | 2015-08-21 | Beigene Ltd | |
| MX2014008071A (es) | 2011-12-31 | 2015-07-06 | Beigene Ltd | Tetra o penta-piridoftalazinonas ciclicas fusionadas como inhibidores de poli(adenosin-difosfato-ribosa)polimerasas. |
| BR112014017833A2 (pt) | 2012-01-20 | 2021-03-23 | Dennis Brown | Uso de hexitóis substituídos incluindo dianidrogalactitol e análogos para tratar doença neoplástica e células-tronco de câncer incluindo glioblastoma multiforme e meduloblastoma |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| PL2938598T3 (pl) * | 2012-12-31 | 2017-05-31 | Cadila Healthcare Limited | Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy) |
| EP2983674A4 (en) | 2013-04-08 | 2017-05-10 | Dennis M. Brown | Therapeutic benefit of suboptimally administered chemical compounds |
| CN105764501A (zh) | 2013-07-26 | 2016-07-13 | 现代化制药公司 | 改善比生群治疗效益的组合物 |
| KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| KR102359214B1 (ko) | 2014-04-04 | 2022-02-07 | 델 마 파마슈티컬스 | 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체 |
| FR3027901B1 (fr) * | 2014-10-31 | 2018-03-16 | Universite De Reims Champagne Ardenne | Nouveaux procedes appartenant a la famille des pyridazinones. |
| US10336707B2 (en) | 2014-12-16 | 2019-07-02 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| DK3307734T3 (da) * | 2015-06-09 | 2020-01-27 | Abbvie Inc | Nukleære receptormodulatorer (ror) til behandling af inflammatoriske og autoimmune sygdomme |
| HK1249504A1 (zh) * | 2015-09-02 | 2018-11-02 | Glaxosmithkline Intellectual Property (No. 2) Limited | 用作溴结构域抑制剂的吡啶酮二甲酰胺 |
| JP6864674B2 (ja) | 2015-10-01 | 2021-04-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ビアリールキナーゼ阻害剤 |
| KR102030016B1 (ko) | 2016-09-05 | 2019-10-08 | 충남대학교산학협력단 | 신규한 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| ES2747768T3 (es) | 2017-03-20 | 2020-03-11 | Forma Therapeutics Inc | Composiciones de pirrolopirrol como activadores de quinasa de piruvato (PKR) |
| CN108383837B (zh) * | 2018-02-09 | 2020-08-11 | 福建医科大学 | 一种氨基取代四氢吡啶并嘧啶类化合物或其可用盐及其制备方法与应用 |
| WO2019212946A1 (en) | 2018-04-30 | 2019-11-07 | Ribon Therapeutics Inc. | Screening methods for parp modulators |
| EP3788040B1 (en) | 2018-04-30 | 2023-04-12 | Ribon Therapeutics Inc. | Pyridazinones as parp7 inhibitors |
| KR102017115B1 (ko) | 2018-05-15 | 2019-09-02 | 충남대학교산학협력단 | 폴리(adp-리보스)폴리머라제-1(parp-1) 관련 질환의 예방 또는 치료용 약학적 조성물 |
| US12053458B2 (en) | 2018-09-19 | 2024-08-06 | Novo Nordisk Health Care Ag | Treating sickle cell disease with a pyruvate kinase R activating compound |
| ES2989438T3 (es) | 2018-09-19 | 2024-11-26 | Novo Nordisk Healthcare Ag | Activación de la piruvato cinasa R |
| US12371421B2 (en) | 2019-04-29 | 2025-07-29 | Ribon Therapeutics, Inc. | Solid forms of a PARP7 inhibitor |
| CN110818908B (zh) * | 2019-08-29 | 2021-12-17 | 杭州市富阳区浙工大银湖创新创业研究院 | 一种用于检测氧化气体的金属有机骨架材料的制备方法 |
| US20220378756A1 (en) | 2019-09-19 | 2022-12-01 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
| US12459899B2 (en) | 2019-10-30 | 2025-11-04 | DIGMBIO, Inc. | Isoquinolinone derivatives, method for preparing the same, and pharmaceutical composition for preventing or treating poly(ADP-ribose) polymerase-1-related diseases, comprising the same as active ingredient |
| WO2021087018A1 (en) * | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| KR20220109401A (ko) * | 2019-10-30 | 2022-08-04 | 리본 테라퓨틱스 인코포레이티드 | Parp7 억제제로서의 피리다진온 |
| US11390608B2 (en) | 2020-04-21 | 2022-07-19 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
| US12060345B2 (en) | 2020-04-21 | 2024-08-13 | Idience Co., Ltd. | Process for preparing a phthalazinone derivative and intermediates thereof |
| WO2021224186A1 (en) * | 2020-05-04 | 2021-11-11 | Institut Curie | New pyridine derivatives as radiosensitizers |
| US12059419B2 (en) | 2020-10-16 | 2024-08-13 | Idience Co., Ltd. | Pharmaceutical composition comprising phthalazinone derivatives |
| WO2022188889A1 (zh) * | 2021-03-12 | 2022-09-15 | 杭州英创医药科技有限公司 | 作为parp7抑制剂的化合物 |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
| EP4312978A2 (en) | 2021-03-27 | 2024-02-07 | TRX Biosciences Limited | Compositions having improved bioavailability of therapeutics |
| CN115477640A (zh) * | 2021-05-31 | 2022-12-16 | 由理生物医药（上海）有限公司 | 作为parp7抑制剂的哒嗪酮类化合物 |
| CN117751108A (zh) * | 2021-07-21 | 2024-03-22 | 南京明德新药研发有限公司 | 哒嗪酮类化合物 |
| EP4378938A4 (en) * | 2021-07-29 | 2025-04-02 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | NEW PARP7 INHIBITOR AND USE THEREOF |
| CN117279907A (zh) * | 2021-08-06 | 2023-12-22 | 成都百裕制药股份有限公司 | 吡咯烷酮衍生物及其在医药上的应用 |
| US20230183216A1 (en) * | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| CN115745971B (zh) * | 2021-12-20 | 2024-07-30 | 北京华森英诺生物科技有限公司 | Parp7抑制剂及其应用 |
| CN116375688B (zh) * | 2021-12-23 | 2025-04-11 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| JP2025509680A (ja) * | 2022-03-14 | 2025-04-11 | ティーアールエックス バイオサイエンシズ リミテッド | 治療薬のバイオアベイラビリティを改善した組成物およびその使用 |
| AU2022451580B2 (en) * | 2022-04-01 | 2024-11-07 | Novostar Pharmaceuticals, Ltd. | Parp7 inhibitor and use thereof |
| CN119968364A (zh) * | 2022-09-30 | 2025-05-09 | 阿兹卡拉疗法公司 | 哒嗪-3(2h)-酮和吡啶-2(1h)-酮parp抑制剂化合物 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025087383A1 (zh) * | 2023-10-26 | 2025-05-01 | 深圳众格生物科技有限公司 | 作为parp7抑制剂的化合物 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5622948A (en) * | 1994-12-01 | 1997-04-22 | Syntex (U.S.A.) Inc. | Pyrrole pyridazine and pyridazinone anti-inflammatory agents |
| IL118631A (en) * | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| CA2205757C (en) * | 1996-05-30 | 2006-01-24 | F. Hoffmann-La Roche Ag | Pyridazinone derivatives and their use as inhibitors of prostaglandin g/h synthase i and ii(cox i and ii) |
| PL223343B1 (pl) | 2000-10-30 | 2016-10-31 | Kudos Pharm Ltd | Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe |
| DE60218458T2 (de) | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
| DE60335359D1 (de) | 2002-04-30 | 2011-01-27 | Kudos Pharm Ltd | Phthalazinonderivate |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| BRPI0408704A (pt) | 2003-03-24 | 2006-03-07 | Hoffmann La Roche | benzil-piridazinonas como inibidores de transcriptase reversa |
| EA200601558A1 (ru) | 2004-02-26 | 2007-08-31 | Инотек Фармасьютикалз Корпорейшн | Производные изохинолинов и способы их использования |
| WO2005090317A1 (en) | 2004-03-23 | 2005-09-29 | F.Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| PE20060285A1 (es) | 2004-03-30 | 2006-05-08 | Aventis Pharma Inc | Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp) |
| JP2007532592A (ja) | 2004-04-15 | 2007-11-15 | エフ．ホフマン−ラ ロシュ アーゲー | ピリダジノン化合物の製造方法 |
| CA2577191A1 (en) | 2004-08-26 | 2006-03-02 | Kudos Pharmaceuticals Limited | 4-heteroarylmethyl substituted phthalazinone derivatives |
| PL1919878T3 (pl) | 2005-07-21 | 2011-03-31 | Hoffmann La Roche | Pochodne pirydazynonu jako agoniści receptora hormonu tarczycy |
| GB0610680D0 (en) | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| DK2120579T3 (da) | 2006-12-28 | 2014-02-03 | Abbvie Inc | Inhibitorer af poly(ADP-ripose)polymerase |
| US20080280910A1 (en) | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20090023727A1 (en) | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
-
2008
- 2008-11-14 ES ES08850429.5T patent/ES2524787T3/es active Active
- 2008-11-14 KR KR1020107013113A patent/KR101641596B1/ko active Active
- 2008-11-14 RU RU2010123874/04A patent/RU2490265C2/ru active
- 2008-11-14 EP EP08850429.5A patent/EP2220073B1/en active Active
- 2008-11-14 NZ NZ585395A patent/NZ585395A/en unknown
- 2008-11-14 MX MX2010005070A patent/MX2010005070A/es active IP Right Grant
- 2008-11-14 WO PCT/GB2008/051063 patent/WO2009063244A1/en not_active Ceased
- 2008-11-14 CN CN2008801155905A patent/CN101855221B/zh active Active
- 2008-11-14 CA CA2704714A patent/CA2704714C/en active Active
- 2008-11-14 AU AU2008322676A patent/AU2008322676B9/en active Active
- 2008-11-14 US US12/739,262 patent/US8268827B2/en active Active
- 2008-11-14 JP JP2010533666A patent/JP5758630B2/ja active Active
-
2010
- 2010-04-08 ZA ZA2010/02466A patent/ZA201002466B/en unknown
- 2010-04-15 IL IL205142A patent/IL205142A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CN101855221A (zh) | 2010-10-06 |
| NZ585395A (en) | 2012-03-30 |
| US8268827B2 (en) | 2012-09-18 |
| JP2011503166A (ja) | 2011-01-27 |
| IL205142A (en) | 2014-09-30 |
| JP5758630B2 (ja) | 2015-08-05 |
| US20100261709A1 (en) | 2010-10-14 |
| ES2524787T3 (es) | 2014-12-12 |
| AU2008322676B9 (en) | 2014-03-27 |
| CA2704714A1 (en) | 2009-05-22 |
| MX2010005070A (es) | 2010-05-24 |
| RU2010123874A (ru) | 2011-12-20 |
| IL205142A0 (en) | 2010-11-30 |
| KR20100087220A (ko) | 2010-08-03 |
| KR101641596B1 (ko) | 2016-07-21 |
| EP2220073B1 (en) | 2014-09-03 |
| WO2009063244A1 (en) | 2009-05-22 |
| BRPI0820236A2 (pt) | 2015-06-16 |
| CN101855221B (zh) | 2013-10-30 |
| AU2008322676A1 (en) | 2009-05-22 |
| AU2008322676B2 (en) | 2013-12-05 |
| EP2220073A1 (en) | 2010-08-25 |
| CA2704714C (en) | 2018-12-04 |
| RU2490265C2 (ru) | 2013-08-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201002466B (en) | Pyridazinone derivatives as parp inhibitors | |
| PL2215075T3 (pl) | Pochodne chinolinonu jako inhibitory PARP | |
| SI2754660T1 (sl) | Piridazinonski derivati | |
| IL202376A0 (en) | Pyridazinone derivatives | |
| ZA201105440B (en) | Pyridazinone derivatives | |
| IL212636A0 (en) | Pyridazinone derivatives | |
| IL200906A0 (en) | Pyridazinone derivatives useful as glucan synthase inhibitors | |
| IL210494A0 (en) | Pyridazine derivatives as smo inhibitors | |
| ZA201005166B (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| ZA201008330B (en) | Pyridazinone derivatives | |
| IL200047A0 (en) | Pyrazole derivatives as 11-beta-hsd1 inhibitors | |
| IL208203A0 (en) | Heterocyclic derivatives | |
| TWI348908B (en) | Imidazolidinone derivatives | |
| EP2222166A4 (en) | INHIBITORS OF HETEROCYCLIC KINASES | |
| IL202034A0 (en) | Heterocyclic indazole derivatives | |
| IL202612A0 (en) | Compositions comprising tryptophan hydroxylase inhibitors | |
| IL196000A0 (en) | 2-arylindole derivatives as npges-i inhibitors | |
| ZA201002580B (en) | Heterocyclic derivatives | |
| ZA200906423B (en) | Pyrazolone derivatives as PDE4 inhibitors | |
| IL205299A0 (en) | Parp inhibitor compounds | |
| ZA200905235B (en) | Pyrazole derivatives as 11-beta-hsd1 inhibitors | |
| GB0714941D0 (en) | Inhibitors | |
| GB0713152D0 (en) | Phosphodlesterase inhibitors |